Couldn't agree more. I will be a patient if the stock keeps on going down and we continue to have more shares issued. And yes, as you said, there [will] be contracts.
I'm sure that's what you meant.
I thought you could only buy shares at .90 if you were a current shareholder. Is that not true? And is it one for one? If I had 400,000 shares, I could see trying to sell 200K shares and then hope to buy back an additional 200K shares at .90.
The question is, why did it drop so far down after a weak quarter and am expected weak current quarter when if one buys for the long term, the outlook is excellent? Do you think the insiders are buying because they want to lose money?
Hemacare is positioning itself as the total solution supporting research and cell therapy.
During 2013, the first year Hemacare entered the bioresearch products and services market, the company added 109 new customers and generated $1.4 million in revenues in just 8 months.
In 2014, Hemacare produced $4.5 million in revenues and added another 99 new customers. In Q4 of 2014, Hemacare launced a non-healthy donor sample product line and expanded into international markets including Europe and Asia. Hemacare is accelerating this expansion by leveraging a network of best-in-class partners already well-established in these regions.
So far in 2015, Hemacare is on pace to produce a near doubling in revenues and achieve substantial progress towward profitability in 2016. Year to date, Hemacare added another 34 customers. This rapid revenue growth gives mgmt a high level of confidence the market will continue to gravitate to the quality products and services Hemacare offers. While up to now, Hemacare's strategy has not been well understood by the marketplace, its current focus on the cellular therapy market is of keen interest to the investment community.
The annual meeting was today. The news, from what I heard from someone who attended, was very positive. Hopefully, HemaCare will come out with a press release to reiterate what was discussed at the meeting.